Economic Evaluation of
Health and Social Care Interventions
Policy Research Unit
Showing posts with label Cancer. Show all posts
Showing posts with label Cancer. Show all posts
Review of methodological quality of cost-effectiveness evaluations of radiotherapy for breat, colorectal, prostate, cervical and head and neck cancer
Output
Barbieri M. et al. What is the quality of economic evaluations of non-drug therapies? A systematic review of economic evaluations of radiotherapy for cancer.Contact
Roberta Ara. Click here to email RobertaReview of methodological quality of cost-effectiveness evaluations of surgical interventions for breast, colorectal or prostate cancer
Output
Ara R, et al. Are policy decisions on surgical procedures in cancer informed by robust economic evidence? A systematic review of economic evidence of surgical interventions for breast, colorectal or prostate cancer.Contact
Roberta Ara. Click here to email RobertaModelling the Cost-Effectiveness of Early Awareness Interventions for the Early Detection of Lung Cancer
Survival rates of lung cancer in England are significantly lower than several countries with similar levels of healthcare expenditure. This may be related to a poor rate of presentation to primary care with symptoms of lung cancer. This research reports the first attempt to assess the cost-effectiveness of campaigns to improve the rate of presentation and in doing so considers the natural history of the disease before diagnosis has occurred.
Outputs
- Invited podium presentation at the second National Awareness and Early Diagnosis Initiative (NAEDI), 17th April 2013
- Poster presentation at the forthcoming annual Public Health England conference 10-11 September 2013
- Unpublished report currently under peer review.
Project team
Sebastian Hinde, Claire McKenna, Mark Sculpher.Contact
Claire McKenna. Click here to email ClaireThe cost-effectiveness of therapies currently used in routine practice
Recent advancements in the routine collection of data on treatment pathways of patients diagnosed with all forms of cancer has facilitated the cost-effectiveness analysis of therapies used in routine practice. This project aims to evaluate the cost-effectiveness of cancer therapies currently used in routine practice.